Clinical Significance of EML4-ALK Fusion Gene and Association with EGFR and KRAS Gene Mutations in 208 Chinese Patients with Non-Small Cell Lung Cancer

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Li, Ying ^a   Li, Yongwen ^a   Yang, Tong ^a   Wei, Sen ^a   Wang, Jing ^a   Wang, Min ^a   Wang, Yuli ^a   Zhou, Qinghua ^a   Liu, Hongyu ^a   Chen, Jun ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARCINOMA; CHINESE; CONTROLLED STUDY; DNA SEQUENCE; EGFR GENE; EML4 ALK FUSION GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; ONCOGENE K RAS; POPULATION GENETICS; PREVALENCE; SEX RATIO; SIGNET RING CARCINOMA; STAINING; SURVIVAL TIME;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC;

EID: 84872330303     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052093     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Jemal A, Center MM, DeSantis C, Ward EM, (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893-1907.
3. Smith W, Khuri FR, (2004) The care of the lung cancer patient in the 21st century: a new age. Semin Oncol 31: 11-15.
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98.
5. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, et al. (2004) Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22: 1103-1109.
6. Govindan R, (2004) Cetuximab in advanced non-small cell lung cancer. Clin Cancer Res 10: 4241s-4244s.
7. Tiseo M, Gelsomino F, Boggiani D, Bortesi B, Bartolotti M, et al. (2011) EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer 71: 241-243.
8. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237-2246.
9. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128.
10. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
11. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566.
12. Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, et al. (2010) Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 17: 889-897.
13. Solomon B, Varella-Garcia M, Camidge DR, (2009) ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 4: 1450-1454.
14. Zhang X, Zhang S, Yang X, Yang J, Zhou Q, et al. (2010) Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 9: 188.
15. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, et al. (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27: 4247-4253.
16. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, et al. (2009) The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115: 1723-1733.
17. Yamashita Y, Minoura K, Taya T, Fujiwara SI, Kurashina K, et al. (2007) Analysis of chromosome copy number in leukemic cells by different microarray platforms. Leukemia 21: 1333-1337.
18. Yoshida A, Tsuta K, Nakamura H, Kohno T, Takahashi F, et al. (2011) Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 35: 1226-1234.
19. Sica G, Yoshizawa A, Sima CS, Azzoli CG, Downey RJ, et al. (2010) A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 34: 1155-1162.
20. Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, et al. (2010) Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res 70: 9827-9836.
21. Riely GJ, Marks J, Pao W, (2009) KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6: 201-205.
22. Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, et al. (2009) EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 174: 661-670.
23. Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, et al. (2011) A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 71: 6051-6060.
24. Yoshida A, Tsuta K, Watanabe S, Sekine I, Fukayama M, et al. (2011) Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 72: 309-315.
25. Bai H, Wang Z, Chen K, Zhao J, Lee JJ, et al. (2012) Influence of Chemotherapy on EGFR Mutation Status Among Patients With Non-Small-Cell Lung Cancer. J Clin Oncol 30: 3077-3083.
26. Lu X, Chen J, Malumbres R, Cubedo Gil E, Helfman DM, et al. (2007) HGAL, a lymphoma prognostic biomarker, interacts with the cytoskeleton and mediates the effects of IL-6 on cell migration. Blood 110: 4268-4277.
27. Sanders HR, Li HR, Bruey JM, Scheerle JA, Meloni-Ehrig AM, et al. (2011) Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. Cancer Genet 204: 45-52.
28. Jokoji R, Yamasaki T, Minami S, Komuta K, Sakamaki Y, et al. (2010) Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol 63: 1066-1070.
29. Lin E, Li L, Guan Y, Soriano R, Rivers CS, et al. (2009) Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 7: 1466-1476.
30. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, et al. (2008) EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 3: 13-17.
31. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, et al. (2008) Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 14: 6618-6624.
32. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, et al. (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14: 4275-4283.
33. Shinmura K, Kageyama S, Tao H, Bunai T, Suzuki M, et al. (2008) EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 61: 163-169.
34. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, et al. (2009) EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22: 508-515.